Dynamic changes of the inflammation‐based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study

David J. Pinato; Georgios Karamanakos; Tadaaki Arizumi; Delali Adjogatse; Y. W. Kim; Justin Stebbing; Masatoshi Kudo; Jeong Won Jang; Rohini Sharma

doi:10.1111/apt.12992

Shared by

Masatoshi Kudo

Dynamic changes of the inflammation‐based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study

Article 2014 en

Authors

DP
David J. Pinato
GK
Georgios Karamanakos
TA
Tadaaki Arizumi

Abstract

1 min read

Normalisation of IBI after TACE is shown to be an independent predictor of survival and may be integrated into the retreatment criteria for repeat TACE in intermediate stage HCC. IBI and its dynamic changes after treatment are validated as a biomarker allowing the stratification of patients with a significant survival advantage following initial TACE.

Related publications

Article2016

Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study

David J. Pinato, Tadaaki Arizumi, Jeong Won Jang, Elias Allara, Puvan Suppiah, Carlo Smirne, Paul Tait, Madhava Pai, G. Grossi, Young Woon Kim, Mario Pirisi, Masatoshi Kudo, Rohini Sharma

Article2019

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study

Masatoshi Kudo, Kazuomi Ueshima, Stephan Chan, Tomohiro Minami, Hirokazu Chishina, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Yoshiyuki Wada, Masafumi Ikeda, Hiroshi Ishii, Namiki Izumi, Naoshi Nishida

Preprint2019

Lenvatinib as an Initial Treatment in Patients with Intermediate-stage Hepatocellular Carcinoma Beyond up-to-seven Criteria and Child-Pugh A Liver Function: A Proof-of-Concept Study

Article2012

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design

Marta Burrel, María Reig, Alejandro Forner, Marta Barrufet, Carlos Rodríguez de Lope, Silvia Tremosini, Carmen Ayuso, Josep M. Llovet, María Isabel Real, Jordi Bruix

Journal of Hepatology

Article2020

Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study.

Masatoshi Kudo, Kazuomi Ueshima, Stephen L. Chan, Tomoko Aoki, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Yoshiyuki Wada, Masafumi Ikeda, Hiroshi Ishii, Namiki Izumi, Atsushi Hiraoka, Hiroshi Aikata, Naoshi Nishida

Dynamic changes of the inflammation‐based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study

Abstract

Discussion(0)

Related publications

Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study

Lenvatinib as an Initial Treatment in Patients with Intermediate-stage Hepatocellular Carcinoma Beyond up-to-seven Criteria and Child-Pugh A Liver Function: A Proof-of-Concept Study

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design

Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study.